Somavert and Foot deformity - a phase IV clinical study of FDA data

Summary:

Foot deformity is reported as a side effect among people who take Somavert (pegvisomant), especially for people who are male, 10-19 old, also take Melatonin, and have Pituitary tumor.

The phase IV clinical study analyzes which people have Foot deformity when taking Somavert. It is created by eHealthMe based on reports of 5,769 people who have side effects when taking Somavert from the FDA, and is updated regularly.

What is Somavert?

Somavert has active ingredients of pegvisomant. eHealthMe is studying from 5,774 Somavert users. Check the latest studies of Somavert.

What is Foot deformity?

Foot deformity (functional disability of foot) is found to be associated with 910 drugs and 707 conditions by eHealthMe. Check the latest studies of Foot deformity.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

5,769 people reported to have side effects when taking Somavert.
Among them, 40 people (0.69%) have Foot deformity.

Among these 40 people:

What is the gender of people who have Foot deformity when taking Somavert? *

female: 10.53 %
male: 89.47 %

What is the age of people who have Foot deformity when taking Somavert? *

What are other drugs people take besides Somavert? *

Synthroid: 36 people, 90.00%
Cortef: 36 people, 90.00%
Melatonin: 36 people, 90.00%
Strattera: 32 people, 80.00%
Sertraline: 22 people, 55.00%
Carbamazepine: 22 people, 55.00%
Primidone: 22 people, 55.00%
Sandostatin: 21 people, 52.50%
Risperidone: 21 people, 52.50%
Propranolol Hydrochloride: 20 people, 50.00%

What are other side effects people have besides Foot deformity? *

Insulin-Like Growth Factor Increased: 39 people, 97.50%
Neoplasm Progression (growth of tumour): 37 people, 92.50%
Blood Growth Hormone Increased: 37 people, 92.50%
Gait Disturbance: 36 people, 90.00%
Nausea (feeling of having an urge to vomit): 36 people, 90.00%
Injection Site Pain: 36 people, 90.00%
Viral Diarrhea: 36 people, 90.00%
Infrequent Bowel Movements: 36 people, 90.00%
Helicobacter Infection (helicobacter pylori (h. pylori) infects stomach): 36 people, 90.00%
Head Injury: 36 people, 90.00%

What are the existing conditions these people have? *

Pituitary Tumor: 36 people, 90.00%
Growth Hormone-Producing Pituitary Tumor: 35 people, 87.50%
Constipation: 31 people, 77.50%
Tremor (trembling or shaking movements in one or more parts of your body): 27 people, 67.50%
Acromegaly (body produces too much growth hormone, leading to excess growth of body tissues): 4 people, 10.00%
Pituitary Tumor Benign: 2 people, 5.00%
Blood Growth Hormone Abnormal: 2 people, 5.00%
Osteoporosis (bones weak and more likely to break): 1 person, 2.50%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 2.50%
High Blood Pressure: 1 person, 2.50%

* Approximation only. Some reports may have incomplete information.

Do you take Somavert and have Foot deformity?

- Check whether Foot deformity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Somavert:

Somavert (5,774 reports)

Foot deformity treatments and more:

Foot deformity (14,397 reports)

Browse all side effects of Somavert:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Foot deformity:

Foot deformity (910 drugs)

Browse all the conditions that are associated with Foot deformity:

Foot deformity (707 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on pegvisomant (the active ingredients of Somavert) and Somavert (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.